Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sergliflozin Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 17/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sergliflozin Etabonate SCHEMBL15827906 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL621807 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL16421550 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL18058588 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL8018797 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL23731198 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| SCHEMBL14634632 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL14634627 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL874080 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4360297 | 0.92 | SLC5A2 (0.86) | SLC5A2SLC5A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | claimed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | claimed |
| US-7371730-B2 | Crystals of glucopyranosyloxybenzyl benzene derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-13 | — | — | US | claimed |
| US-20050119192-A1 | Crystals of glucopyranosyloxybenzyl benzene derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | claimed |
| EP-1489089-A1 | CRYSTALS OF GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | claimed |
| US-20200367808-A1 | Diabetes Control Using Postprandial Feedback | NATH RATTAN (US) | 2020-11-26 | — | — | US | disclosed |
| US-10743813-B2 | Diabetes control using postprandial feedback | NATH RATTAN (US) | 2020-08-18 | — | — | US | disclosed |
| US-20170258395-A1 | Diabetes Control Using Postprandial Feedback | NATH RATTAN (US) | 2017-09-14 | — | — | US | disclosed |
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | disclosed |
| EP-2236137-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER DISEASES | ASTELLAS PHARMA INC (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140227289-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-08-14 | — | — | US | disclosed |
| US-20050119192-A1 | Crystals of glucopyranosyloxybenzyl benzene derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| US-6872706-B2 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-29 | — | — | US | disclosed |
| US-20050065098-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. | 2005-03-24 | — | — | US | disclosed |
| EP-1489089-A1 | CRYSTALS OF GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1489089-A1 | CRYSTALS OF GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040018998-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| WO-2003080635-A1 | CRYSTALS OF GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
| EP-1329456-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119192-A1 | Crystals of glucopyranosyloxybenzyl benzene derivative | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885CYP3A4 717/4885 |
| US-20050065098-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885CYP3A4 260/4885 |
| US-20040018998-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885CYP3A4 224/4885 |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC5A2 11/4885SLC5A1 15/4885CYP3A4 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.